Astrazeneca Down 3% Despite Citigroup Upgrade

By: via Benzinga
On Tuesday, Citigroup upgraded shares of Astrazeneca (NYSE: AZN) from Neutral to Buy and raised the price target from $20.80 to ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.